{"id":"etravirine-tablets","safety":{"commonSideEffects":[{"rate":"14%","effect":"Nausea"},{"rate":"13%","effect":"Diarrhea"},{"rate":"12%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL308954","moleculeType":"Small molecule","molecularWeight":"435.29"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits the replication of HIV-1 by binding to the reverse transcriptase enzyme.","oneSentence":"Non-nucleoside reverse transcriptase inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:52:15.560Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT04208373","phase":"PHASE1","title":"A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-12-20","conditions":"Healthy","enrollment":32},{"nctId":"NCT04273165","phase":"PHASE2","title":"Safety and Efficacy of Etravirine in Friedreich Ataxia Patients","status":"COMPLETED","sponsor":"IRCCS Eugenio Medea","startDate":"2020-09-17","conditions":"Friedreich Ataxia","enrollment":30},{"nctId":"NCT04630002","phase":"PHASE1","title":"Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-10-28","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT00537394","phase":"PHASE3","title":"Optimizing Treatment for Treatment-Experienced, HIV-Infected People","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-01","conditions":"HIV Infections","enrollment":517},{"nctId":"NCT01504841","phase":"PHASE1, PHASE2","title":"Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-03-14","conditions":"HIV Infections","enrollment":26},{"nctId":"NCT02212379","phase":"PHASE2","title":"Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2015-01","conditions":"HIV-1 Infection","enrollment":170},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT01641367","phase":"PHASE4","title":"A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-02-22","conditions":"HIV-1 Infection","enrollment":545},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00855335","phase":"PHASE3","title":"A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2009-04-09","conditions":"HIV, HIV Infections, Pregnancy","enrollment":77},{"nctId":"NCT01199731","phase":"PHASE2","title":"Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2010-10-05","conditions":"Infection, Human Immunodeficiency Virus","enrollment":30},{"nctId":"NCT02063360","phase":"PHASE1","title":"DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-02-01","conditions":"Infection, Human Immunodeficiency Virus","enrollment":42},{"nctId":"NCT01045369","phase":"PHASE4","title":"A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects","status":"COMPLETED","sponsor":"Therapeutic Concepts","startDate":"2010-01","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT01500616","phase":"PHASE3","title":"Telaprevir Open-Label Study in Co-Infected Patients","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2012-06","conditions":"Hepatitis C, Chronic","enrollment":122},{"nctId":"NCT00959894","phase":"PHASE2","title":"Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-09","conditions":"HIV Infections","enrollment":80},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT01741844","phase":"","title":"A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2012-09","conditions":"Acquired Immune Deficiency Syndrome","enrollment":57},{"nctId":"NCT01422330","phase":"PHASE4","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-09","conditions":"Human Immunodeficiency Virus (HIV) Infection","enrollment":211},{"nctId":"NCT00254046","phase":"PHASE3","title":"TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2005-11","conditions":"HIV","enrollment":616},{"nctId":"NCT01254656","phase":"PHASE2","title":"A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022","status":"TERMINATED","sponsor":"Pfizer","startDate":"2011-02","conditions":"HIV-1","enrollment":108},{"nctId":"NCT01615601","phase":"","title":"An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Janssen Inc.","startDate":"2011-10","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":77},{"nctId":"NCT00896051","phase":"PHASE2","title":"TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2009-08","conditions":"HIV Infections, Acquired Immunodeficiency Syndrome","enrollment":50},{"nctId":"NCT01427504","phase":"NA","title":"Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2011-08","conditions":"Hepatitis C, HIV","enrollment":26},{"nctId":"NCT00128830","phase":"PHASE2","title":"A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2005-06","conditions":"Human Immunodeficiency Virus Type 1","enrollment":211},{"nctId":"NCT01876966","phase":"PHASE1","title":"Interaction Between Etravirine or Darunavir/Ritonavir and Artemether / Lumefantrine","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2011-03","conditions":"HIV","enrollment":33},{"nctId":"NCT00903682","phase":"PHASE2","title":"A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2009-06","conditions":"HIV Infection, HIV, Acquired Immunodeficiency Syndrome","enrollment":157},{"nctId":"NCT01090648","phase":"PHASE1","title":"TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2010-03","conditions":"HIV-Infections","enrollment":49},{"nctId":"NCT00255099","phase":"PHASE3","title":"TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2005-12","conditions":"HIV","enrollment":593},{"nctId":"NCT00871234","phase":"PHASE1","title":"Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study","status":"COMPLETED","sponsor":"Indiana University","startDate":"2009-04","conditions":"Endothelial Function, Lipids, Insulin Resistance","enrollment":28},{"nctId":"NCT00792324","phase":"PHASE3","title":"Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2008-06","conditions":"HIV","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Etravirine Tablets","genericName":"Etravirine Tablets","companyName":"IRCCS Eugenio Medea","companyId":"irccs-eugenio-medea","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etravirine is a small molecule that inhibits the human immunodeficiency virus type 1 reverse transcriptase. It is used to treat Human Immunodeficiency Virus (HIV) Infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}